ALT · Altimmune Inc.

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

910 Clopper Road, Gaithersburg, MD, 20878, United States
Biotechnology
Healthcare

Market Cap

297.7M

52 Wk Range

$1.50 - $6.44

Previous Close

$1.53

Open

$1.53

Volume

4,681,210

Day Range

$1.38 - $1.53

Enterprise Value

74.7M

Cash

265.1M

Avg Qtr Burn

-37.74M

Insider Ownership

0.47%

Institutional Own.

73.64%

Qtr Updated

Sep 30th 2026